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Background: Qualitative and quantitative changes in human mitochondrial DNA (mtDNA) have been implicated in
various cancer types. A 4,977 bp deletion in the major arch of the mitochondrial genome is one of the most
common mutations associated with a variety of human diseases and aging.
Methods: We conducted a comprehensive study on clinical features and mtDNA of 104 colorectal cancer patients
in the Wenzhou area of China. In particular, using a quantitative real time PCR method, we analyzed the 4,977 bp
deletion and mtDNA content in tumor tissues and paired non-tumor areas from these patients.
Results: We found that the 4,977 bp deletion was more likely to be present in patients of younger age (≤65 years,
p = 0.027). In patients with the 4,977 bp deletion, the deletion level decreased as the cancer stage advanced (p =
0.031). Moreover, mtDNA copy number in tumor tissues of patients with this deletion increased, both compared
with that in adjacent non-tumor tissues and with in tumors of patients without the deletion. Such mtDNA content
increase correlated with the levels of the 4,977 bp deletion and with cancer stage (p < 0.001).
Conclusions: Our study indicates that the mtDNA 4,977 bp deletion may play a role in the early stage of
colorectal cancer, and it is also implicated in alteration of mtDNA content in cancer cells.
Background
Colorectal cancer is one of the leading human malig-
nancies [1]. While its morbidity and mortality have
declined in western countries in recent years, both the
incidence and deaths caused by this cancer have
increased significantly in recent years in Asia [2], parti-
cularly in China [3]. Both genetic and environmental
factors contribute to colorectal cancer development.
Based on a study on cohorts of twins from Sweden,
Denmark and Finland, heritable factors contributed
about 35% to colorectal cancer [4], while in another
nationwide family study conducted with 9.6 million
Swedish people, around 13% of colorectal susceptibility
was attributed to genetic effects [5]. However, up to
now, only 6% of colorectal cancer can be ascribed to
mutations in particular genes [6]. Among those genes
associated with predispositions for colorectal cancer are
adenomatous polyposis coli (APC), a tumor suppressor
involving cell adhesion, signal transduction and tran-
scription activation, and DNA mismatch repair (MMR)
genes [6,7].
Mitochondria, known as the cellular power plants, also
regulate cell death and cell proliferation [8,9]. Defects in
mitochondrial function have long been hypothesized to
play a role in tumorigenesis [10]. Mitochondria possess
their own genomes. Human mtDNA encodes 13 essential
subunits of the oxidative phosphorylation (OXPHOS)
system as well as 2 rRNAs and 22 tRNAs used for mito-
chondrial translation [11]. Alterations in mtDNA both
qualitatively (mutations) [12-14] and quantitatively
(mtDNA copy number) [15] have been associated with
many human diseases including neurodegenerative dis-
eases, metabolic diseases and various types of cancer
[16-18].
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damage and at the same time is sensitive to such
damage. It has also been shown that oxidative modified
DNA is especially prone to mispairing of repetitive ele-
ments and is correlated with deletions [19]. In fact, large
scale deletions were among the first mtDNA mutations
identified to cause human diseases [20,21]. Up to now,
more than 100 deletions have been reported to be asso-
ciated with various diseases (http://www.mitomap.org/).
Among these deletions, a 4,977-bp deletion occurring
between two 13-bp direct repeats at positions 13447-
13459 and 8470-8482 has attracted tremendous interests
since it is the common cause of several sporadic diseases
including Pearson’s syndrome, Kearns-Sayre syndrome
(KSS) and chronic progressive external ophthalmoplegia
(CPEO) [13,22], and is therefore called the “common”
deletion. This deletion also accumulates in many tissues
during aging, and has been used as an mtDNA damage
biomarker [18,23].
mtDNA mutations, including both point mutations
and deletions, have been identified in various types of
human cancer [16,17,24]. In one of the first comprehen-
sive studies of mtDNA in cancer cells, it was demon-
strated that among ten colorectal cancer cell lines, seven
of them exhibited mtDNA mutations [25]. In another
study focused on the major control region of mtDNA,
the “displacement loop” (D-loop) in French colorectal
cancer patients, the presence of tumor D-loop mutations
correlated with poor prognosis [26].
To address the question if the mtDNA 4,977-bp dele-
tion plays a role in pathogenesis and development of
colorectal cancer, we studied 104 colorectal cancer
patients recently admitted in the First Affiliated Hospital
of Wenzhou Medical College and carried out a systema-
tic investigation into their clinicopathological features
and characterized their mtDNA, in particular the 4,977-
bp deletion and the mtDNA content, in the tumor tis-
sues and nearby non-tumor areas.
Methods
Samples collection
Paraffin-embedded tumor tissues and paired adjacent
non-tumor tissues were collected from 104 unrelated
colorectal cancer patients prior to any chemotherapy,
radiotherapy or pharmacothera p ya tt h eF i r s tA f f i l i a t e d
Hospital of Wenzhou Medical College between October,
2006 and March, 2008. Informed consent from all
patients in this study was obtained under protocols
approved by the Wenzhou Medical College Ethics Com-
mittee. The patients ranged in age from 33 to 87 years
(mean ± SD, 65.58 ± 11.49), and were classified accord-
ing to the tumor-node-metastasis (TNM) staging system
(American Joint Committee on Cancer): 15 were at
stage I, 45 at stage II, 39 at stage III and 5 at stage IV.
Ten-micron sections were cut from paraffin blocks and
classifications were confirmed by a senior pathologist
using a standard hematoxylin & eosin staining protocol.
Detection of the mtDNA 4,977-bp deletion
Tumor and non-tumor tissues on the slides were
extracted separately under a microscope. Genomic DNA
was isolated as previously described [27]. To screen for
the 4,977-bp deletion in mtDNA, nested PCR analysis
was performed in order to detect low levels of deletion
(Figure. 1). Two pairs of nested primers for detection of
the 4,977-bp deletion were, 1F: AACCACAGTTT-
CATGCCCATC; 1R: TGTTAGTAAGGGTGGGGAA-
GC; 2F: ACCCTATTGCACCCCCTCTAC; and 2R:
CTTGTCAGGGAGGTAGCGATG. The PCR condition
was set as: pre-denaturation at 94°C for 5 min; then 30
cycles at 94°C for 10 s, 58 °C for 45 s and 72 °C for
50 s; and a final extension at 72 °C for 10 min. PCR
products were then electrophoresed on a 2% agarose
gel. By design (Figure. 1A), the presence of the 4,977-bp
deletion was indicated by the appearance of a 358-bp
band, which was verified by sequencing analysis (Figure.
1B). On the other hand, wild-type mtDNA as the tem-
plate would not yield any PCR products under such
conditions because of the large flanking region (>5-kb)
(Figure. 1A). All PCR experiments included a negative
Figure 1 Detection of the mtDNA 4,977-bp deletion. (A) Human
mitochondrial genome with or without the 4,977-bp deletion; the
positions of primers used in nested PCR for detecting this deletion
were 1F (8192-8212), 1R (13663-13643), 2F (8261-8281) and 2R
(13595-13575). The fragment was too large for wildtype mtDNA
(>5 kb) to be amplified with the PCR conditions used for detection.
(B) Confirmation of the 4,977 bp deletion. Representative sequencing
profile of the PCR products from the patients carrying the deletion.
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and a positive control with mtDNA harboring a 4,977-
bp deletion which was isolated in the laboratory pre-
viously from a prostate cancer patient.
Determination of mtDNA content and levels
of the 4,977 bp deletion
The mtDNA content was measured by a real-time PCR
on cytochrome c oxidase I (COX I) gene and normal-
ized by simultaneous measurement of nuclear DNA
encoded b -actin genes. QPCR was carried out using an
ABI 7900HT Fast Real-Time PCR System (Applied Bio-
systems) in a 20 μl reaction in different tubes containing
0.5 μM each of the forward and reverse primers, 0.1 pM
for each probe (COX I and b-actin genes) and 500 pg of
DNA sample for mtDNA and 10 ng for nDNA. The
PCR conditions were 95°C for 15 min, followed by 40
cycles of 95°C for 15 s, and 60°C for 60 s. The threshold
cycle number (Ct) values of the b-actin gene and the
mitochondrial COXI gene were determined.
The 4,977 bp deletion level was measured by real-time
PCR on deletion product (Figure. 1) and normalized by
simultaneous measurement of mtDNA COX I.
Each measurement was carried out in triplicate and
normalized against a serial dilution of a control DNA
sample and then the quantity of each target gene in our
samples was calculated according to the corresponding
standard curve.
The primer and probe information is as follows:
For mtDNA COX I: Forward, TTCGCCGACCGTT-
GACTATTCTCT; Reverse, AAGATTATTACAAATG
CATGGGC.
For nuclear b-actin: Forward, ACCCACACTGTGCC-
CATCTAC; Reverse, TCGGTGAGGATCTTCATGA
GGTA.
For mtDNA 4,977 bp deletion: Forward, CCTTACAC-
TATTCCTCATCACC; Reverse, TGTGGTCTTTGGAG-
TAGA AACC
Probes: COX I, FAM-AACGACCACATCTACAACG
TTATCGTCAC-ECLIPSE; b-actin, FAM-ATGCCCTC
CCCCATGCCATCC-ECLIPSE. 4,977 -bp deletion,
FAM-TGGCAGCCTAGCATTAGCAGG-ECLIPSE
Standard curves for deleted mtDNA were generated
from a prostate cancer patient, and for COX I and
b-actin genes they were obtained using a human osteo-
sarcoma-derived cell line (U2OS) DNA. mtDNA content
was calculated by dividing the amount of total mitochon-
drial DNA into the amount of nuclear gene. The mtDNA
deletion level was expressed as the ratio of content of
deleted mitochondrial DNA to total mtDNA content.
Statistical analysis
Categorical variables were analyzed using chi-square test
or Fisher’s exact test and continuous variables were
examined using Student’s t-test. In order to adjust for
the contribution of each clinicopathologic characteristic,
logistic regression and linear regression analysis were
also performed. All statistical results were calculated
w i t hS P S S1 6 . 0s o f t w a r ea n dapv a l u el e s st h a n0 . 0 5
was considered statistically significant.
Results
Detection of the mtDNA 4,977 bp deletion in
colorectal cancer patients
Of the 104 colorectal cancer patients, 20 (19.23%)
showed the 4,977 -bp deletion in either tumor or nearby
non-tumor tissues. Among them, 10 (9.62% of total)
were found to be harboring the deletion in both tumor
and non-tumor tissues, 7 (6.73%) only showed it in
tumor tissues, and 3 (2.88%) only in non-tumor tissues.
Overall, 17 patients were found to carry the 4,977-bp
deletion in tumors, and 13 patients carried it in nearby
non-tumor tissues (Table 1). We also analyzed some
clinical characteristics and other risk factors for colorec-
tal cancer in these patients including age, body mass
index (BMI), tumor cell differentiation status, lymph
node metastasis (LN metastasis) detection and tumor
stage. As shown in Table 1, BMI seemed not to be a
contributing factor for occurrence of the 4,977-bp dele-
tion in either tumor or non-tumor tissues. Examination
of the clinicopathologic features listed above failed to
reveal any significant association between the occur-
rence of the 4,977-bp deletion and tumor cell differen-
tiation, LN metastasis and tumor stage (Table 1).
Surprisingly, unlike what was expected as the 4,977-bp
deletion accumulated during aging, we found the
patients under 65 years old were more likely to carry
this deletion in tumor tissues. Although 12 out of 48
(25%) of colorectal cancer patients in this younger age
group were found to harbor the 4,977-bp deletion in
tumor tissues, only 5 of 56 (8.93%) older patients carried
this deletion (p = 0.027) (Table 1). This age-related dif-
ference only existed in tumor tissues, and no differences
were detected in the nearby non-tumor tissues (Table
1). Moreover, it appeared that in patients under 65,
tumor tissues were more likely to carry the 4,977-bp
deletion compared with the nearby non-tumor tissues
(OR = 1.952; 95% CI: 0.694-5.491). In contrast, in the
older age group, there was no such difference (OR =
0.817; 95% CI: 0.234-2.850). Interestingly, while the ages
of 7 patients carrying 4,977-bp deletion only in tumor
tissue were wide-ranging, all three patients with this
deletion only in non-tumor areas were over 65.
Level of the 4,977 bp deletion and colorectal
cancer development
We then measured levels of the 4,977-bp mtDNA dele-
tions in the patients carrying it. We found that the
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4.77% of total mitochondrial DNA in tissues carrying
this deletion. Interestingly, although failed to achieve the
significance, the average and mean levels of deletion in
17 tumor tissues appeared lower than those in non-
tumor areas (Figure. 2A). Moreover, in patients who
carried the deletion in both tumor and nearby non-
tumor tissues, the deletion levels were almost always
lower in tumor tissues compared with the non-tumor
areas (Figure. 2B). Interestingly, the P-value was 0.047
when the outlier case 199 was excluded in analysis.
These results indicate a negative selection for the 4,977-
bp deletion in cancer cells.
To further explore the role of the 4,977-bp deletion in
the pathogenesis of colorectal cancer, we examined the
relationship between deletion level and some risk factors
or clinicopathologic features in patients carrying this
deletion in tumor tissues or non-tumor tissues. Interest-
ingly, we found after multiple linear regression analysis
that the deletion level in tumor tissues decreased as the
cancer stage advanced (p = 0.031) (Table 2). No correla-
tions were found between deletion levels in tumor or
non-tumor tissues with age, BMI, differentiation or LN
metastasis.
The 4,977 bp deletion level and mtDNA copy
number in colorectal cancer patients
Alterations in mtDNA content have been reported in
increasing numbers of cancer types [28]. To investigate
mtDNA copy number changes and to determine if there
was a correlation between the common deletion and the
overall mtDNA content in colorectal cancer, we further
analyzed mtDNA copy numbers in these colorectal can-
cer patients. We first plotted the mtDNA copy numbers
vs. 4,977 bp deletion levels in tumor and non-tumor tis-
sues of all 20 colorectal cancer patients carrying this
deletion. Surprisingly, we found that, with the decline of
the common deletion, mtDNA copy number increased
in both tumor and non-tumor tissues (Figure. 3). Never-
theless, the slope of increase of mtDNA copy number
with decrease of common deletion level in tumor tissues
were much steeper compared with nearby non-tumor
areas, indicating a stronger effect of the cancer nuclear
background on modulating the mtDNA content in pre-
sence of common deletion.
To verify the difference in mtDNA copy number
c h a n g e si nt u m o r sa n dn e a r b yn o n - t u m o rt i s s u e s ,w e
compared them in patients carrying the 4,977-bp dele-
tion in both tumor and non-tumor areas (Figure. 4A),
and in patients carrying this deletion only in tumor tis-
sues (Figure. 4B) or only in non-tumor tissues (Figure.
4C). In almost all cases, we found that mtDNA copy
numbers were higher in tumor tissues compared with
the nearby non tumor areas. To further determine if the
4,977-bp deletion was implicated in the alteration of
mtDNA content in colorectal cancer, we also analyzed
the mtDNA copy numbers in 18 age- and gender-
matched control colorectal cancer patients who did not
Table 1 Detection of the mtDNA 4,977 bp deletion in tumor and non-tumor tissues of 104 colorectal cancer patients
N Deletion detected in
non-tumor tissues
p-value OR (95% CI) Deletion detected in
tumor tissues
p-value OR (95% CI)
Cases 104 13 (12.50%) 17 (16.35%)
Age
≤65 48 7 (14.58%) 0.552 1.423 12 (25.00%) 0.027* 3.400
>65 56 6 (10.71%) (0.443-4.566) 5 (8.93%) (1.101-10.495)
BMI#
<18 3 0 0.248 – 0 0.286 –
18-24 65 8 (11.76%) 11 (16.18%)
≥24 25 5 (20.00%) 6 (24.00%)
Differentiation#
Poor 22 2 (9.09%) 0.772 0.590 3 (13.64%) 0.813 0.680
Moderate 69 10 (14.49%) (0.119-2.924) 13 (18.84%) (0.175-2.647)
LN metastasis
Positive 43 8 (18.60%) 0.114 2.560 8 (18.60%) 0.601 1.321
Negative 61 5 (8.20%) (0.775-8.453) 9 (14.75%) (0.465-3.753)
Stage
I+II 60 5 (8.33%) 0.134 0.409 9 (15.00%) 0.665 0.794
III+IV 44 8 (18.18%) (0.124-1.350) 8 (18.18%) (0.280-2.255)
N, case number; BMI, body mass index; Differentiation, tumor cell differentiation status; LN metastasis, lymph node metastasis; Stage, cancer stage classified
according to the tumor-node-metastasis (TNM) staging system (American Joint Committee on Cancer); OR, odds ratio; P-values were calculated by chi-square test,
*statistically significant; 95% CI, 95% confidence interval; # incomplete data.
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unlike what we observed in patients with the deletion,
we did not see a consistent difference in mtDNA copy
numbers between tumor and non tumor tissues.
We further compared mtDNA copy number in tumor
and non-tumor tissues from patients with and without
the mtDNA 4,977-bp deletion. As shown in Figure. 5,
while there was a significant difference between the
mtDNA copy numbers in non-tumor tissues between
colorectal cancer patients with or without the 4,977-bp
deletion (20 with and 18 without, age- and gender-
matched patients), mtDNA content in the tumor tissues
was higher in patients with the mtDNA common dele-
tion (p = 0.002).
mtDNA copy number as a potential marker in
colorectal cancer
To further determine if the mtDNA copy number could
also serve as a biomarker for development of colorectal
cancer, we analyzed the relationship between mtDNA
copy number and cancer stage in these patients. Since
we showed previously that in patients with the common
deletion, cancer stage was correlated with the 4,977-bp
deletion level (Table 2), we examined the relationship
between mtDNA content and cancer stage in patients
with and without the common deletion. As shown in
Figure. 6, in patients with the 4,977-bp deletion, it
appeared that as the cancer stage advanced, the mtDNA
copy number increased (p = 0.056) in the tumors, while
no such correlation was observed in the nearby non-
tumor areas (p = 0.151) (Figure. 6A). The correlation
between mtDNA content in tumor tissues and cancer
Figure 2 Comparison of mtDNA 4,977-bp deletion levels
between tumor and non-tumor tissues. (A) deletion levels in 17
and 13 patients carrying the deletion in tumor (closed circle and
solid line)and non-tumor tissues(open circle), respectively. The solid
lines represent the mean values. (B) paired deletion levels in tumor
and non-tumor tissues from the same patients in 10 cases who
carried the deletion in both tissues. p-values were obtained by
independent-samples T test for (A) and paired-samples T test for (B).
Table 2 Multiple linear regression analysis of the
relationship between mtDNA 4,977 bp deletion level and
age, BMI, metastasis status and stage of cancer in tumor








Non-tumor Age 0.000 -0.002 to
0.001
0.245
BMI 0.000 -0.003 to
0.004
0.859
LN metastasis -0.023 -0.074 to
0.029
0.337
Stage -0.011 -0.043 to
0.020
0.415
Tumor Age 0.000 0.000 to
0.000
0.141
BMI 0.000 0.000 to
0.001
0.471
LN metastasis -0.006 -0.014 to
0.002
0.115
Stage -0.005 -0.010 to
0.000
0.031*
BMI, body mass index; LN metastasis, lymph node metastasis; Stage, tumor-
node-metastasis (TNM) stage; Coefficients: the effect of the corresponding
characteristics on deletion level; 95% CI, 95% confidence interval; *statistically
significant.
Figure 3 Relationship between mtDNA content and the 4,977-
bp deletion level. The deletion level in tumor (closed circle and
solid line) and non-tumor (open circle and dot line) tissues from 20
patients who carried the deletion are plotted against the mtDNA
content. R
2 indicates the strength of a linear relationship between
the two parameters.
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ear regression analysis (p < 0.001) (Table 3). However,
in the 18 age- and gender-matched patients without the
common deletion, no correlations were detected in both
tumor and non-tumor tissues (Figure. 6B and Table 3).
To further investigate the implication of mtDNA com-
mon deletion and mtDNA content in colorectal cancer
patients, we carried out a multiple linear regression ana-
lysis of relationship between mtDNA content and age,
metastasis status and cancer stage in tumor and non-
tumor tissues in patients with or without the common
deletion. As shown in Table 3, significant correlations
only existed in tumor tissues of colorectal cancer
patients carrying the mtDNA common deletion. Besides
the cancer stage, with increasing mtDNA copy number
in tumor tissues with the common deletion, the cancer
was more likely to be LN metastatic (p = 0.002).
Discussion
mtDNA mutations have been implicated in various
human diseases including cancer [24], a long-term
Figure 4 Comparison of mtDNA content between tumor and non-tumor tissues. mtDNA content in tumor (closed circle) and non-tumor
(open circle) tissues are compared in patients (A) carrying the mtDNA 4,977-bp deletion in both tissues (B) carrying the mtDNA 4,977-bp
deletion only in tumor tissues, (C) carrying the mtDNA 4,977-bp deletion only in non-tumor tissues, and (D) age and gender matched patients
without the deletion. All p values were derived from paired-samples T test analysis.
Figure 5 Comparison of mtDNA content between patients with
and without the 4, 977-bp mtDNA deletion. mtDNA contents in
tumor and non-tumor tissues from 20 patients with 4,977 bp
deletion and 18 age- and gender-matched patients without the
deletion were compared (tumor, closed circle/triangle; non-tumor,
open circle/triangle; circle, with common deletion; triangle, without
common deletion). The solid lines represent the mean values. All p
values were derived from independent-samples T test analysis.
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genetic and epigenetic alterations. Among the mtDNA
mutations, the 4,977-bp deletion is one of the most fre-
quent [23]. Several studies have found the mtDNA
4,977-bp deletion in various types of cancer, including
in cancer of the breast, endometrial, esophagus, sto-
mach, head and neck, liver, lung, mouth, kidney, skin
and thyroid [24,28]. However, in some cases, the inci-
dence and level of the 4,977 bp deletion were lower in
the tumor tissues compared with nearby non-tumor tis-
sues from the same patients[29]. Thus, the role of this
common deletion in tumorigenesis is intriguing, but lar-
gely perplexing.
In our first finding, unlike the age-dependent accumu-
lation that was expected, the 4,977 bp deletion was
detected more frequently in tumor tissues of patients
younger than 65 (12/48, or 25%) compared to patients
over 65 (5/56, or 8.9%) (p = 0.027). This result indicated
that there is possibly a negative selection for the com-
mon deletion in tumor tissues during aging. In addition,
as previously reported with thyroid, renal and liver can-
cer patients [29], we found the deletion level in tumor
tissues was likely to be lower than that in the nearby
non-tumor areas. In particular, in 10 patients carrying
the 4,977-bp deletion in both tumor and nearby non-
tumor tissues, the deletion levels were almost all lower
in tumor tissues, indicating a negative selection for the
common deletion in the cancer cells. It is also interest-
ing to note that among these 10 subjects, patient 199
was at an advanced tumor stage and exhibited meta-
static features, and showed the biggest difference in the
deletion levels between tumor and non-tumor tissues
and the highest level of the common deletion in the
non-tumor areas (Figure. 2B). On the other hand,
patient 137 exhibited very similar deletion level in
tumor tissues and the nearby non-tumor tissues (Figure.
2B), and he was at the early stage of cancer and exhib-
ited no metastasis. Furthermore, among all 17 patients
who carried the deletion in tumor tissues, there was a
good correlation after multiple linear regression analysis
(p = 0.031) between the decrease in deletion level in
tumor tissues and the stage of advancement in the
cancer.
To explain the observed results, we hypothesize that,
as we previously found in tumorigenesis studies on cells
carrying mtDNA with heteroplasmic and homoplasmic
mutations in the complex I subunit ND5 gene [30], the
4,977-bp mtDNA deletion could function in cancer
development as follows: in the initial stage, when cancer
cells are under stress because of a carcinogenic insult or
oxidative stress damage, the deletion emerges. Because
of the replicative advantage of smaller mtDNA, mtDNA
with the 4,977-bp deletion is enriched to a certain level
Table 3 Multiple linear regression analysis of relationships between mtDNA content and age, metastasis status and
stage of cancer in tumor and non-tumor tissues in patients with or without the 4,977 bp mtDNA deletion
mtDNA content Patients without 4977 bp deletion Patients with 4977 bp deletion
Characteristics Coefficients (B) 95% CI for B p-value Coefficients (B) 95% CI for B p-value
Non-tumor Age 0.191 -0.220 to 0.602 0.333 0.027 -0.055 to 0.108 0.493
LN metastasis 25.029 -0.328 to 50.386 0.053 2.137 -1.464 to 5.739 0.224
Stage 14.460 -1.759 to 30.679 0.076 1.690 -0.614 to 3.993 0.138
Tumor Age 0.017 -0.052 to 0.087 0.602 0.064 -0.033 to 0.161 0.180
LN metastasis -0.330 -4.619 to 3.959 0.871 7.880 3.578 to 12.182 0.002*
Stage -0.100 -2.844 to 2.643 0.938 5.839 3.088 to 8.590 0.000*
LN metastasis, lymph node metastasis; Stage, tumor-node-metastasis (TNM) stage; Coefficients: effect of the corresponding characteristics on deletion level;
95% CI, 95% confidence interval; * statistically significant.
Figure 6 Relationship between mtDNA content and cancer
stage. mtDNA content is plotted again the cancer stage in tumor
(closed circle) and non-tumor (open circle) tissues of patients (A)
with the 4, 977-bp mtDNA deletion, and (B) without the deletion.
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grade pathways [31]. Retrograde regulation is a commu-
nication pathway from mitochondria to the nucleus, and
is usually used to describe the cellular responses to
changes in the functional state of mitochondria. One of
the mechanisms suggested to play a role in the retro-
grade response was mitochondrial stress, which is sup-
ported by changes in mitochondrial membrane potential
and calcium elevation [31]. However, at certain stage of
tumorigenesis, it may become more important to have a
functional respiratory chain than an inhibited one to
sustain rapid cell proliferation. As a result, compared
with the nearby non-tumor tissues, mtDNA with the
common deletion becomes diluted out in tumor tissues.
Low mtDNA content has been reported to be asso-
ciated with increased risk of renal cancer carcinoma
[32], and a decrease in mtDNA copy number in cancer
tissues has been found also in gastric cancer [33], breast
cancer [34] and hepatocellular carcinoma [35]. On the
other hand, an increase in mtDNA content was reported
in the majority of renal oncocytomas [36], head and
neck cancer [37], endometrial cancer [38], ovarian can-
cer [39] and colorectal cancer [40]. It is therefore sug-
gested that the change in mtDNA content is cancer type
specific [28,34]. However the underlying molecular
mechanisms of alteration in mtDNA in cancer cells are
largely unclear.
Our results strongly suggest that the 4,977-bp deletion
is important in the specific up-regulation of mtDNA
content in tumor tissues. The mtDNA content in tumor
tissue of almost all of 20 patients who carried the
4,977-bp deletion was higher than that in the nearby
non-tumor areas. The only exception was patient 137
(Figure. 4A), who was in her early stage of cancer and
without detection of metastasis in the lymph nodes. On
t h eo t h e rh a n d ,p a t i e n t1 8 0( F i g u r e .4 A ) ,w h os h o w e d
the biggest difference in the levels of mtDNA content
between tumor and non-tumor areas, was in the term-
inal stage of cancer and with metastasized lymph nodes.
These results support the notion that tumor background
favors high mtDNA copy number with the presence of
the 4,977-bp deletion. As this deletion removes all or
part of the genes encoding four complex I subunits, one
complex IV subunit, two complex V subunits and five
tRNA genes, which are indispensable for maintaining
normal mitochondrial function [41], the mtDNA
4,977-bp deletion could lead to energy production cata-
strophes [42] and abnormal ROS generation [43]. Since
the deletion levels observed here were well below the
threshold for any bioenergetics consequences [42], the
up-regulation is more likely due to a retrograde reaction
[31] rather than a simple compensatory effect for ATP
production. This retrograde signal is amplified in a col-
orectal cancer background.
Conclusions
In conclusion, our investigation provides evidence that
the mtDNA 4,977-bp deletion plays a role in the early
stage of colorectal cancer, but it is selected against once
the tumor enter the rapid growth phase. Our results
also demonstrate that in tumors with this common dele-
tion, mtDNA content could increase specifically in
tumor tissues, probably due to a retrograde effect. These
results also indicate that both the 4,977-bp deletion and
mtDNA content may serve as a biomarker for colorectal
cancer in some patients.
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